From the monthly archives: May 2012
Will BioPorto deliver a signed sealed delivered and binding Distribution Agreement with a major Diagnostic Company in the second quarter of 2012 ?
What’s Your opinion ….???
Another interesting article about NGAL as a marker for AKI, from the University of Liege
NGAL biomarqueur de lésion rénale
Docteur at Hospital du Nord in Saint Etienne France Amandine Gagneux-Brunon and Belgian Docteurs at the University of Liege , Pierre Delanaye, Delphine LeGrand, Etienne Cavalier and Christophe Mariat have made an interesting article about the potential […]
Dagens Chat om Q1, redigeret lidt..nok ikke nok, der er stadig kommentarer af Druen med 🙂 Admin11.22 på slaget… der landede i det ihvertfald i min indbox Guest Ray11:24 AM 2,1 mil i Ngal salg fint Muldyr11:24 AM Omsat for 518.000 admin11:24 AM 2,1 mil ja… 1 mil over hvad jeg havde troet – ah ok… […]
Today BioPorto released its Q1 figures. Nothing much was expected, and nothing much was indeed the outcome. I will, as always, start with focusing on the area(s) that are disappointing. But don’t despair yet – hopefully I’ll end on a lighter note
If we look at the turnover – it was perhaps in accordance with […]
In another article the expansion of NGAL Test is not seen as a rapid event, as more Multi-Center trials are requested.
Just as we couldn’t get our hands down, the Internet strikes back.. If not fully – then at least partially.
Doctors Stefan Herget-Rosenthal,, Jochen Metzger, Amaya Albalat, Vasiliki Bitsika and Harald Mischak
from Department of […]
“The performance of NGAL in these and other clinical studies appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, suggesting that we will likely see rapid expansion of its use in the coming years.”
Pumpa (Medicoinvestor Investigator Extraordinaire) found this interesting article:
In a paper from 2 Canandian Docteurs at the […]
Dagens EPO chat – omkring begrundelse for afvisningen – jeg har sakset en lille bitte smule og rettet et par favestejl 🙂 Den ligger her som indlæg til benefice for vore amerikanske læsere i San Diego og i Illinois – så behøver de ikke lede så meget 🙂
– ubeskedent nok starter jeg med mig selv […]
The Reasons for the decision by the EPO, regarding the revokation of the NGAL cutoff-patent are now available at the EPO website, in a document titled: “The Grounds for the decision”
In short – the OD does not find that the invention fulfills article 83 and article 100 (summary on page 11) – […]
Following EPO presentation of the minutes of the Oral Proceedings earlier today, We have been in contact with BioPorto.
According to the information BioPorto have received – a wrritten explanation on the reasoning of the OD is under way. EPO have informed BioPorto that the explanatory note is to be received sometime next week.
BioPorto […]
As you are all painfully aware of, EPO (European Patent Organisation) held Oral Proceedings on the fate of the courted NGAL cutoff-patent, on Feb. the 8th
Now – after ONLY three months (sic !) the details of the proceedings are made public.
All -the relevant documents can be found here.
It is, […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
